Author:
Dr.
John Maggioncalda
Provenge is the first FDA
approved form of immunotherapy for the treatment of metastatic prostate
cancer. Patients must have a rising PSA, despite castrate levels of
testosterone, and some demonstrable form of metastatic disease by CT/MRI,
ultrasound or bone scan. Potential patients must also be healthy enough
to receive Provenge with at least a 6-month life expectancy and no or limited
pain from their metastases.
Provenge is not a form of
chemotherapy; it is considered immunotherapy. The treatment uses the
body’s own cancer fighting cells and energizes them to attack prostate cancer
cells. Once approved for treatment a patient will have blood drawn and
the immune cells separated from the red cells. These immune cells are
then stimulated so that they will begin attacking the prostate cancer
cells. The immune cells are reintroduced into the body after stimulation
and the process is repeated two more times. These three treatments are
all that is required and the total treatment takes 4-5 weeks. The side
effects of Provenge can include bruising from the needle sticks, fatigue,
backache, and low-grade fevers.
Once a patient receives
Provenge the progress of their disease will continue to be monitored by their
Urologist or Oncologist. There is often no direct reduction in a patient’s
PSA level after treatment but, studies have shown an improvement in overall
survival compared to subjects that did not receive the treatment.
Patients are still able to receive other forms of chemotherapy once Provenge is
administered.
If you are a patient with
metastatic, castrate-resistant prostate cancer, I encourage you to talk with
your Oncologist or Urologist about Provenge to see if it is an option for
you. Remember, not every patient may be a good candidate for Provenge.